Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 184-192

  Coffman, Lan ^a   Mooney, Collin ^a   Lim, Jaeyoung ^a   Bai, Shoumei ^a   Silva, Ines ^a   Gong, Yusong ^a   Yang, Kun ^a   Buckanovich, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ETRA; ETRB; Macitentan; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CISPLATIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; MACITENTAN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER STEM CELL; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCTION CHEMOTHERAPY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; OVARY TUMOR; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ETRA; ETRB; MACITENTAN; OVARIAN CANCER;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PEPTIDES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84873465919     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22959     Document Type: Article

References (45)

1. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest 2009; 39(Suppl 2):74-7; PMID:19335749; http://dx.doi.org/10.1111/j.1365-2362.2009.02123.x.
2. Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett 2005; 222:129-38; PMID:15863261; http://dx.doi.org/10.1016/j.canlet.2004.08.029.
3. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005; 24:766-76; PMID:16274297; http://dx.doi.org/10.1089/dna.2005.24. 766.
4. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004; 2:16; PMID:15165288; http://dx.doi.org/10.1186/1479- 5876-2-16.
5. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3:110-6; PMID:12563310; http://dx.doi.org/10.1038/nrc990.
6. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res 1999; 59:720-7; PMID:9973223.
7. Kojima K, Nihei Z. Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol 1995; 4:309-15; PMID:8809953; http://dx.doi.org/10.1016/ S0960-7404(10)80043-X.
8. Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M, et al. High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am J Gastroenterol 1993; 88:248-52; PMID:8380950.
9. Shankar A, Loizidou M, Aliev G, Fredericks S, Holt D, Boulos PB, et al. Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg 1998; 85:502-6; PMID:9607532; http://dx.doi.org/10.1046/j.1365-2168.1998. 00660.x.
10. Bagnato A, Spinella F, Rosanò L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer 2005; 12:761-72; PMID:16322321; http://dx.doi.org/10.1677/erc.1.01077.
11. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000; 157:1537-47; PMID:11073813; http://dx.doi.org/10.1016/S0002- 9440(10)64791-8.
12. Morbidelli L, Orlando C, Maggi CA, Ledda F, Ziche M. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 1995; 269:H686-95; PMID:7653633.
13. Rosanò L, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 2002; 103(Suppl 48):306S-9S; PMID:12193110.
14. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157:1703-11; PMID:11073829; http://dx.doi.org/10.1016/S0002-9440(10)64807-9.
15. Hoosein MM, Dashwood MR, Dawas K, Ali HM, Grant K, Savage F, et al. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19:775-82; PMID:17700263; http://dx.doi.org/10.1097/MEG. 0b013e3282c563de.
16. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12:6296s-300s; PMID:17062717; http://dx.doi.org/10.1158/1078-0432.CCR-06-0929.
17. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17:2350-60; PMID:21220476; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2325.
18. Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 2011; 13:167-79; PMID:21403842.
19. James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010; 106:966-73; PMID:20840318; http://dx.doi.org/10.1111/j.1464-410X.2010. 09638.x.
20. Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia 2010; 12:941-5; PMID:21076619.
21. Ziche M, Morbidelli L, Donnini S, Ledda F. ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol 1995; 26(Suppl 3):S284-6; PMID:8587389.
22. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28-36; PMID:18157142; http://dx.doi.org/10.1038/nm1699.
23. Sidharta PN, van Giersbergen PL, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011; 67:977-84; PMID:21541781; http://dx.doi.org/10.1007/s00228-011- 1043-2.
24. Raja SG. Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis. Curr Opin Investig Drugs 2010; 11:1066-73; PMID:20730702.
25. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011; 71:3991-4001; PMID:21498635; http://dx.doi.org/10.1158/0008-5472.CAN-10-3175.
26. Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 2010; 70:8674-83; PMID:20959470; http://dx.doi.org/10.1158/0008-5472.CAN-10- 1917.
27. Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009; 7:49; PMID:19545375; http://dx.doi.org/10.1186/1479-5876-7-49.
28. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002; 161:2295-309; PMID:12466143; http://dx.doi.org/10.1016/S0002-9440(10)64505-1.
29. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133:704-15; PMID:18485877; http://dx.doi.org/10.1016/j.cell.2008.03. 027.
30. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 2012; 322:1-7; PMID:22334034; http://dx.doi.org/10.1016/j.canlet.2012.02.002.
31. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009; 28:209-18; PMID:18836486; http://dx.doi.org/10.1038/onc. 2008.374. 32. Landen CN Jr., Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther 2010; 9:3186-99; PMID:20889728; http://dx.doi.org/10.1158/1535-7163. MCT-10-0563.
32. Sampaio AL, Rae GA, Henriques MM. Role of endothelins on lymphocyte accumulation in allergic pleurisy. J Leukoc Biol 2000; 67:189-95; PMID:10670579.
33. Wang HH, Hsieh HL, Yang CM. Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9. J Cell Physiol 2010; PMID:21660948.
34. Ma HJ, Zhu WY, Wang DG, Yue XZ, Li CR. Endothelin-1 combined with extracellular matrix proteins promotes the adhesion and chemotaxis of amelanotic melanocytes from human hair follicles in vitro. Cell Biol Int 2006; 30:999-1006; PMID:16990029; http://dx.doi.org/10.1016/j.cellbi.2006.07.007.
35. Masamune A, Satoh M, Kikuta K, Suzuki N, Shimosegawa T. Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol 2005; 11:6144-51; PMID:16273641.
36. Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, et al. Endothelin-1 is a potent stimulator of alpha1beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun 2002; 299:555-61; PMID:12459174; http://dx.doi.org/10.1016/S0006-291X(02)02693- 1.
37. Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 2004; 104:2107-15; PMID:15213100; http://dx.doi.org/10.1182/blood-2003-10-3559.
38. Chang B, Liu G, Xue F, Rosen DG, Xiao L, Wang X, et al. ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol 2009; 22:817-23; PMID:19329942.
39. De Angeli S, Del Pup L, Febas E, Conconi MT, Tommasini M, Di Liddo R, et al. Adrenomedullin and endothelin-1 stimulate in vitro expansion of cord blood hematopoietic stem cells. Int J Mol Med 2004; 14:1083-6; PMID:15547678.
40. Steg AD, Bevis KS, Katre AA, Ziebarth A, Alvarez RD, Zhang K, et al. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 2011; PMID:22142828.
41. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al.; Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110:1959-66; PMID:17886253; http://dx.doi.org/10.1002/cncr.22996.
42. Nelson JB, Love W, Chin JL, Saad F, Schulman CC, Sleep DJ, et al.; Atrasentan Phase 3 Study Group. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008; 113:2478-87; PMID:18785254; http://dx.doi.org/10.1002/cncr.23864.
43. Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia 2010; 12:941-5; PMID:21076619.
44. Kim S-J, Kim JS, Kim SW, Yun SJ, He J, Brantley E, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol 2012; 5:39-47; PMID:22348175.
45. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17:2350-60; PMID:21220476; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2325.